Ligand Pharmaceuticals Inc revenue
Ligand Pharmaceuticals Inc's revenue was $268m in fiscal 2025, up 60.4% on the year before. Since fiscal 2009 ($38.9m) it has grown at a compound 12.8% a year. Over the last twelve months it was $254m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39 | 24 | 30 | 31 | 49 | 65 | 72 | 109 | 141 | 251 | 120 | 164 | 242 | 196 | 131 | 167 | 268 | 254 |
| Growth on the year before | — | −39.6% | +27.6% | +4.5% | +56.0% | +31.8% | +11.4% | +51.5% | +29.5% | +78.2% | −52.2% | +36.0% | +47.7% | −18.8% | −33.1% | +27.3% | +60.4% | — |
| Gross profit | — | — | — | — | — | — | — | 103 | 136 | 245 | — | — | — | — | — | — | — | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Royalty | $161M | ▲ 48.0% |
| Intangible Royalty Assets | $133M | ▲ 39.0% |
| Contract Revenue and Income | $66.9M | ▲ 143.4% |
| Contract Revenue | $66.9M | ▲ 143.4% |
| Income From Divestiture Transactions | $53.1M | — |
| Material Sales Captisol | $40.2M | ▲ 30.2% |
| Material Sales Captisol Core | $40.2M | ▲ 30.2% |
| Royalty Kyprolis | $35.5M | ▼ 7.4% |
| Filspari | $32M | ▲ 162.5% |
| Financial Royalty Assets | $28.5M | ▲ 111.7% |
| QARZIBA | $23.7M | ▲ 113.5% |
| Royalty Rylaze | $13.3M | ▼ 2.9% |
| Royalty Other | $10.4M | ▲ 38.5% |
| Capvaxive | $10.1M | ▲ 1506.9% |
| Ohtuvayre | $9.8M | ▲ 1071.7% |
| Royalty Teriparatide Injection | $8.1M | ▼ 0.9% |
| Vaxneuvance | $7.4M | ▲ 42.8% |
| License Fees | $7M | ▲ 259.5% |
| Services | $6.8M | ▼ 73.3% |
| Royalty Evomela | $5.9M | ▼ 31.5% |
| Financial Royalty Other | $4.7M | ▲ 103.4% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Ligand Pharmaceuticals Inc's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Ligand Pharmaceuticals Inc | $254m | 1.0% | 18.2% |
| Rhythm Pharmaceuticals, Inc. | $240m | 53.5% | 76.3% |
| Anaptysbio, Inc | $238m | 92.9% | 163.9% |
| Phathom Pharmaceuticals, Inc. | $275m | 86.8% | — |
| Ideaya Biosciences, Inc. | $234m | -70.1% | 94.0% |
| Puma Biotechnology, Inc. | $231m | -2.9% | 0.2% |
Compare with peers
- Rhythm Pharmaceuticals, Inc. revenue
- Anaptysbio, Inc revenue
- Phathom Pharmaceuticals, Inc. revenue
- Ideaya Biosciences, Inc. revenue
- Puma Biotechnology, Inc. revenue
Head to head: LGND vs RYTMANAB vs LGNDLGND vs PHAT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies